Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07276724 · ClinicalTrials.gov registry record · Phase 3

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

A Phase 3 study of Severe Asthma, sponsored by Generate Biomedicines.

Recruiting
Registry status
Phase 3
Development phase
786
Enrollment target
13
Study locations

NCT07276724 is a Phase 3 study of Severe Asthma that is actively recruiting participants, run by Generate Biomedicines. The registered enrollment target is 786 participants, below the 3,768-participant average among 9 other Severe Asthma trials with a reported enrollment target (79% lower). The trial reports 13 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07276724, a Phase 3 study of Severe Asthma, is actively recruiting participants, sponsored by Generate Biomedicines.

RECRUITING
Registry status
Phase 3
Development phase
786 participants
Enrollment target
13
Study locations

Study Summary

The objective of this study is to assess the potential for GB-0895 treatment to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers. The study details include: Study treatment: randomized to receive either GB-0895 or placebo administered every 6 months over 52 weeks. Visit frequency: every 1-2 months after the first month.

Conditions Studied

Severe Asthma

Interventions

  • DRUG Placebo
  • DRUG GB-0895

Study Locations (13)

Florida

  • Research Site 12 - Doral
  • Research Site 03 - Hialeah
  • Research Site 04 - Miami
  • Research Site 01 - Miami Lakes
  • Research Site 08 - North Miami
  • Research Site 10 - Palm Springs
  • Research Site 02 - Tampa

Texas

  • Research Site 07 - Dallas
  • Research Site 11 - Houston
  • Research Site 09 - Houston
  • Research Site 05 - Lewisville

California

  • Research Site 13 - West Hills

Michigan

  • Research Site 06 - Flint

Trial Details

FieldValue
Enrollment Target 786 participants
Start Date 2025-12-03
Est. Completion 2028-12
Phase Phase 3

Sponsor

Generate Biomedicines

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07276724

The ClinicalTrials.gov registry entry for NCT07276724 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 786 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,768-participant average among 9 other Severe Asthma trials with a reported enrollment target (79% lower). The listed sponsor is Generate Biomedicines, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Severe Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07276724 reports 13 study locations spanning 4 distinct geographic areas - top geographies include Florida, Texas, California.

Frequently Asked Questions

What is clinical trial NCT07276724 about?

NCT07276724 is a clinical study titled "A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)". The objective of this study is to assess the potential for GB-0895 treatment to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers. The study details include: Study treatment: randomized to recei...

What is the current status of trial NCT07276724?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 786 participants. The study started on 2025-12-03. Estimated completion is 2028-12.

What conditions does trial NCT07276724 study?

This clinical trial studies the following conditions: Severe Asthma.

What interventions are being tested in trial NCT07276724?

The interventions under investigation include: Placebo (DRUG), GB-0895 (DRUG).

Who is sponsoring clinical trial NCT07276724?

This trial is sponsored by Generate Biomedicines, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07276724 being conducted?

This trial has 13 study locations across California, Florida, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Severe Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Severe Asthma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.